Drug details

Opdivo (nivolumab injection)

type of PD-1PD-L1 Inhibitors, Antineoplastics Monoclonal Antibody

Opdivo (nivolumab) is a human monoclonal antibody used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; and to treat metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

This drug may have the following side effects:
  • difficulty breathing,
  • nausea,
  • loss of appetite,
  • itching,
  • fever,
  • skin rash,
  • lightheadedness,
  • confusion,
  • chills,
  • stomach pain,
  • clay-colored stools,
  • chest pain,
  • dizziness,
  • dry mouth,
  • joint pain,
  • cough,
  • blood in the urine,
  • little or no urination,
  • increased urination,
  • fruity breath odor,
  • mood changes,
  • mouth sores,
  • increased hunger or thirst,
  • seizures,
  • yellowing of the eyes or skin (jaundice),
  • dry skin,
  • neck stiffness,
  • sensitivity to light,
  • unusual weakness,
  • hallucination,
  • general ill feeling,
  • changes in vision,
  • loss of contact with reality,
  • changes in the amount of urine,
  • weight gain or loss
  • severe muscle pain or weakness,
  • swelling of the face, lips, or tongue,
  • bloody or watery diarrhea,
  • black tarry stools,
  • headache with fever,
  • loss of memory,
  • redness, blistering, peeling or loosening of the skin, including inside the mouth,
  • dark yellow or brown urine,
  • right upper abdominal pain,
  • swelling of your ankles, feet, and hands, and
The following drugs are related to Opdivo, either as a replacement or used together:
  • Krazati (adagrasib tablets)
  • Adstiladrin (nadofaragene firadenovec-vncg suspension, for intravesical use)
  • Proleukin (aldesleukin for injection)
  • Rybrevant (amivantamab-vmjw for injection)
  • Balversa (erdafitinib tablets)
  • Welireg (belzutifan tablets)
  • Mektovi (binimetinib tablets)
  • Cabometyx (cabozantinib tablets)
  • Tabrecta (capmatinib tablets)
  • Cotellic (cobimetinib tablets)
  • Cosela (trilaciclib for injection)
  • Tafinlar (dabrafenib capsules)
  • Vizimpro (dacomitinib)
  • Padcev (enfortumab vedotin-ejfv for injection)
  • Rozlytrek (entrectinib capsules)
  • Exkivity (mobocertinib capsules)
  • Fotivda (tivozanib capsules)
  • Lytgobi (futibatinib tablets)
  • Hepzato (melphalan for injection)
  • Yervoy (ipilimumab injection)
  • Keytruda (pembrolizumab for injection)
  • Zepzelca (lurbinectedin for injection)
  • Mekinist (trametinib tablets)
  • Portrazza (necitumumab intravenous injection)
  • Opdualag (nivolumab and relatlimab-rmbw injection)
  • Odomzo (sonidegib capsules)
  • Pemfexy (pemetrexed injection for intravenous use)
  • Retevmo (selpercatinib capsules)
  • Tazverik (tazemetostat tablets)
  • Zelboraf (vemurafenib)